Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2017

View Archived Issues

Dendright extends collaboration with Janssen and adds Arthritis Queensland as a partner

Eisai, Chugai and Roche sign agreements for flunitrazepam rights in Japan

Telix and Wilex sign license agreement for Redectane

Bristol-Myers Squibb patents IRAK-4 inhibitors

Sumitomo Dainippon Pharma report compounds for treatment of cancer

European Commission confirms orphan drug designation for TB-403 for medulloblastoma

Team in Portugal describes antimalarial agents

AnaMar reports 5-HT2B receptor antagonists

GlaxoSmithKline patents EZH2 inhibitors for cancer

Pierre Fabre reports Plk-1 inhibitors

177Lu-PSMA-617 demonstrates favorable safety and high efficacy in patients with mCRPC

Results from second pivotal trial of ulipristal acetate for abnormal uterine bleeding

Bivalent Vaxwave vaccine shows in vivo efficacy in models of cytomegalovirus infection

Evotec and MaRS Innovation announce launch of Fibrocor Therapeutics

NRC supports Fedora's development of antimicrobial product candidates

AstraZeneca updates status of durvalumab trials in first-line NSCLC

FDA designates NS-065 an orphan drug for the treatment of Duchenne muscular dystrophy

Horizon Discovery broadens gene-editing capabilities

Audentes Therapeutics gives update on programs at J.P. Morgan meeting

Novogene to acquire Pacific Biosciences' Sequel Systems

CytomX initiates first-in-human study of CX-072 to treat solid tumors and lymphomas

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...